论文信息 - TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer - 字舞流文

TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer

L. Saltz | F. Galimi | V. Haddad | Y. Hei | Cheng-Pang Hsu | L. Schwartzberg | A. Cohn | L. Dreisbach | C. Fuchs | L. Yee | M. Kozloff | Yang Pan | M. Fakih | A. Sabin